Glaukos to Present 12-Month Stent and Travoprost Implant Results at ASCRS Meeting
Glaukos will present multiple scientific abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10–13, including 12-month outcomes for third-generation trabecular micro-bypass stents and intracameral travoprost implant efficacy. It will sponsor a symposium on Epioxa™, its FDA-approved epithelium-on corneal cross-linking therapy, on April 10 and exhibit at booth 407.
1. ASCRS Annual Meeting Participation
Glaukos will exhibit at booth 407 during the ASCRS Annual Meeting in Washington, D.C., from April 10–13, 2026, showcasing its ophthalmic technologies across scientific sessions and on-demand posters.
2. Key Scientific Presentations
Glaukos’s abstracts include 12-month outcomes for standalone third-generation trabecular micro-bypass stents, clinical designs for a novel keratoconus screening device, 12-month single-center results of the travoprost intracameral implant, and real-world outcomes combining stents with intracameral implants or cataract surgery.
3. Epioxa™ Educational Symposium
On April 10, Glaukos will sponsor an educational symposium introducing Epioxa™, the first FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment, featuring expert faculty discussing safety, efficacy and clinical applications.
4. Strategic Pipeline Impact
These presentations and the Epioxa™ symposium aim to reinforce Glaukos’s leadership in micro-invasive glaucoma surgery, intracameral drug delivery and corneal cross-linking, potentially accelerating clinical adoption of iDose® TR and Epioxa™ therapies.